Pulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Trading Up 1.5 %

NASDAQ PULM opened at $6.00 on Friday. The company has a fifty day simple moving average of $4.21 and a 200 day simple moving average of $2.81. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $8.44. The company has a market cap of $21.91 million, a P/E ratio of -2.27 and a beta of 1.54.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.